Modulation of Monoaminergic Systems by Antidepressants in the Frontal Cortex of Rats After Chronic Mild Stress Exposure

• Published in: Molecular neurobiology 2019-11, Vol.56 (11), p.7522-7533
• Main Authors: Martín-Hernández, David, Pereira, Marta P., Tendilla-Beltrán, Hiram, Madrigal, José L. M., García-Bueno, Borja, Leza, Juan C., Caso, Javier R.
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Antidepressants; Antidepressive Agents - pharmacology; Antidepressive Agents - therapeutic use; Biogenic Monoamines - metabolism; Biomedical and Life Sciences; Biomedicine; Cell Biology; Chronic Disease; Citalopram; Cortex (frontal); Desipramine; Drug therapy; Duloxetine; Exposure; Frontal Lobe - drug effects; Frontal Lobe - metabolism; Frontal Lobe - pathology; Male; Membrane Transport Proteins - metabolism; Mental depression; Models, Biological; Neurobiology; Neurology; Neurosciences; Neurotransmission; Norepinephrine; Norepinephrine - metabolism; Rats, Wistar; Receptors, Adrenergic - metabolism; Receptors, Serotonin - metabolism; Rodents; Serotonin; Serotonin - metabolism; Stress, Psychological - drug therapy
• ISSN: 0893-7648; 1559-1182
• DOI: 10.1007/s12035-019-1619-x

The standard pharmacological treatment of the major depressive disorder (MDD) is still grounded in a monoaminergic approach. Consequently, antidepressant treatments pursue to heighten serotonergic and noradrenergic neurotransmissions. Thus, the aim of this study was to assess the impact of exposure to a well-characterized animal model, the chronic mild stress (CMS) on serotonin (5-HT) and noradrenaline (NE) levels, and reuptake transporters and receptors in the frontal cortex (FC) of CMS-exposed rats. Moreover, considering the diverse pharmacological profiles of existing antidepressants and the large number of patients not responding to treatments, we have investigated whether generally utilized antidepressants can modulate their expression. Male Wistar rats were exposed to CMS and some of them treated with desipramine, escitalopram, or duloxetine. Possible changes in the described monoaminergic neurotransmission elements were evaluated. CMS induced differences in the expression of reuptake transporters and receptors involved in the monoaminergic neurotransmission pointing towards the weakening of their signaling. CMS antidepressant-treated rats showed an improvement of the monoaminergic tone, being desipramine and duloxetine more influential than escitalopram over noradrenergic elements and having the three antidepressant-tested effects on serotonergic transmission. In summary, there are molecular alterations on the monoaminergic neurotransmission in FC induced by CMS exposure. Besides, antidepressant treatments modulate the elements of these neurotransmission systems differentially.